Clinical trial shows Ziihera improves survival for advanced HER2-positive GEA

AI-generated NewsSnap summary based on source reporting.
Published: 2026-08-31
Category: health
Source: Jazz Pharmaceuticals plc
Original source

Jazz Pharmaceuticals announced positive interim results from its Phase 3 HERIZON-GEA-01 trial, showing Ziihera combined with chemotherapy significantly improved overall survival. This treatment demonstrated superiority over existing therapy for adults with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma, potentially offering a new first-line option for this cancer.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai